Reaction
Smoke Sensitivity reporting signals
As of the last recalculation, Smoke Sensitivity appears in 302 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is OMALIZUMAB (PRR 249.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Omalizumab | 153 | 249.8 | 250.2 |
| Ciclesonide | 16 | 85.4 | 85.5 |
| Baricitinib | 10 | 73.9 | 74.0 |
| Oxybutynin Chloride | 9 | 72.9 | 73.0 |
| Fluticasone Propionate And Salmeterol Xinafoate | 48 | 65.3 | 65.4 |
| Fluticasone Furoate And Vilanterol Trifenatate | 22 | 45.4 | 45.4 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 26.7 | 26.7 |